PRODUCT INFORMATION



OX40/CD134 (human, recombinant)

Item No. 31842

Overview and Properties

ACT35, IMD16, TNFRSF4, Tumor Necrosis Factor Receptor Superfamily Member 4 Synonyms:

Source: Active recombinant C-terminal human IgG1 Fc His-tagged OX40 expressed in HEK293

Amino Acids: 29-216 P43489 **Uniprot No.:** Molecular Weight: 48.2 kDa

Storage: -80°C (as supplied)

Stability: ≥1 year

Purity: ≥85% estimated by SDS-PAGE Lyophilized from sterile PBS, pH 7.4 Supplied in:


Endotoxin Testing: <1.0 EU/µg, determined by the LAL endotoxin assay

Protein

Concentration: batch specific mg/ml **Bioactivity:** See figures for details


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



Lane 1: MW Markers Lane 2: OX40/CD134

SDS-PAGE Analysis of OX40/CD134. This protein has a calculated molecular weight of 48.2 kDa. It has an apparent molecular weight of approximately 68 kDa by SDS-PAGE under reducing conditions due to glycosylation.



OX40/CD134 Binding in Functional ELISA. Immobilized cynomolgus mFc-TNFSF4 at 10 μ g/ml (100 μ l/well) can bind human OX40/CD134. The EC₅₀ value of human OX40/CD134 is $0.23-0.55 \mu g/ml$.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 04/22/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

OX40, also known as TNF receptor superfamily member 4 (TNFRSF4), is a type I transmembrane glycoprotein and the cognate receptor for the T cell co-stimulatory molecule OX40L (TNFSF4: Item No. 32065).1 OX40 assembles into trimers, with each monomer containing three cysteine-rich domains (CRDs) that bind OX40L and a cytoplasmic tail that interacts with TNF receptor-associated factor 1 (TRAF1), -2, -3, and -5 to induce a variety of intracellular signaling cascades, including NF-κB, ERK, PI3K, and Akt pathways. 1,2 OX40 is transiently expressed on CD4⁺ and CD8⁺ T cells in response to antigen stimulation in humans and is localized to lipid rafts.^{1,3} Binding of an OX40 trimer to trimeric OX40L, expressed by antigen-presenting cells (APCs), including dendritic cells (DCs), macrophages, and B cells, forms a hexameric OX40-OX40L complex that promotes effector T cell phenotype and function, proliferation, survival, and memory.³ Increased OX40 levels have been found in inflamed tissues isolated from patients with a variety of autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus (SLE), or rheumatoid arthritis.3 Cayman's OX40/CD134 (human, recombinant) protein can be used for binding assays. This protein is a disulfide-linked homodimer. The reduced monomer, composed of OX40 (amino acids 29-216) fused to His-tagged human IgG1 Fc at its C-terminus, consists of 436 amino acids, has a calculated molecular weight of 48.2 kDa, and a predicted N-terminus of Leu29 after signal peptide cleavage. As a result of glycosylation, the monomer migrates at approximately 68 kDa by SDS-PAGE under reducing conditions.

References

- 1. Buchan, S.L., Rogel, A., and Al-Shamkhani, A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. *Blood* **131(1)**, 39-48 (2018).
- 2. Croft, M., So, T., Duan, W., et al. The significance of OX40 and OX40L to T-cell biology and immune disease. *Immunol. Rev.* **229(1)**, 173-191 (2009).
- 3. Webb, G.J., Hirschfield, G.M., and Lane, P.J.L. OX40, OX40L and autoimmunity: A comprehensive review. *Clin. Rev. Allergy Immunol.* **50(3)**, 312-332 (2016).

PHONE: [800] 364-9897 [734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM